Is Eteplirsen Approved Outside the US?
No, eteplirsen (Exondys 51) is not approved for use outside the United States. The FDA granted accelerated approval in 2016 for treating Duchenne muscular dystrophy (DMD) in patients with confirmed exon 51 skipping mutations amenable to exon 51 skipping.[1] No regulatory agencies in Europe, Canada, Japan, Australia, or other major markets have approved it as of the latest data.
Why Hasn't It Gained Approval in Europe?
The European Medicines Agency (EMA) rejected eteplirsen in 2018 after review, citing insufficient evidence of clinical benefit from Sarepta Therapeutics' submission. The Committee for Medicinal Products for Human Use (CHMP) concluded that surrogate endpoints, like increased dystrophin production, did not reliably predict meaningful improvements in muscle function or survival.[2] Sarepta withdrew its appeal, halting further EU pursuit.
Approval Status in Japan, Canada, and Australia
- Japan: The Pharmaceuticals and Medical Devices Agency (PMDA) has not approved eteplirsen. Sarepta has not publicly filed or advanced an application there, unlike some other DMD therapies.
- Canada: Health Canada denied market authorization in 2021, echoing EMA concerns over unproven efficacy despite accelerated US approval.[3]
- Australia: The Therapeutic Goods Administration (TGA) lists no approval. Access remains limited to compassionate use or clinical trials.
What About Other Countries or Ongoing Efforts?
Eteplirsen lacks approval in Latin America, Asia (beyond potential trials), or the Middle East. Sarepta focuses on next-generation DMD drugs like Elevidys (delandistrogene moxeparvovec), approved in the US in 2023 but facing similar international hurdles. No active filings for eteplirsen appear in global registries like WHO's international clinical trials database.
How Do Patients Access It Outside the US?
Non-US patients rely on expanded access programs, named-patient supply from Sarepta, or clinical trials (e.g., via ClinicalTrials.gov, NCT05126758 for long-term studies). These are rare and not equivalent to commercial approval. Costs exceed $300,000 annually in the US, complicating international import.[4]
Patent Protection and Biosimilar Outlook
Eteplirsen's key US patents, like US 7,807,856 for phosphorodiamidate morpholino oligomers, expire around 2026-2031.[5] No international approvals mean no biosimilars are in development globally.
Sources
[1]: FDA Approval Letter for Exondys 51
[2]: EMA Rejection Assessment Report
[3]: Health Canada Decision Summary
[4]: Sarepta Patient Access
[5]: DrugPatentWatch.com - Eteplirsen Patents